Presentation is loading. Please wait.

Presentation is loading. Please wait.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Published byἈράχνη Κωνσταντόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial."— Presentation transcript:

1 Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. NO: nitric oxide; CO: cardiac output; PAH-CHD: PAH associated with congenital heart disease; LV: left ventricle; RV: right ventricle; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance. Reproduced from [7] with permission from the publisher. Karen M. Olsson, and Richard Channick Eur Respir Rev 2016;25: ©2016 by European Respiratory Society

Download ppt "Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial."

Similar presentations

Recommended algorithm for perioperative management of patients with pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) in.

Recommended algorithm for perioperative management of patients with pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) in.
Guideline for approaching the differential diagnosis of pulmonary hypertension. CHD, congenital heart disease; CO, cardiac output; CT, contrast-enhanced.

Guideline for approaching the differential diagnosis of pulmonary hypertension. CHD, congenital heart disease; CO, cardiac output; CT, contrast-enhanced.
Meghan E. Sise, Andrew M. Courtwright, Richard N. Channick 

Meghan E. Sise, Andrew M. Courtwright, Richard N. Channick 
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Diagnostic algorithm for pulmonary arterial hypertension (PAH).

Diagnostic algorithm for pulmonary arterial hypertension (PAH).
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.

Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.
REVEAL pulmonary arterial hypertension (PAH) risk score.

REVEAL pulmonary arterial hypertension (PAH) risk score.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.
An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.
Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.
Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)
Relationship between exercise mPAP and cardiac output.

Relationship between exercise mPAP and cardiac output.
3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).
Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Similar presentations

Ads by Google